MX2021014093A - Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. - Google Patents
Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.Info
- Publication number
- MX2021014093A MX2021014093A MX2021014093A MX2021014093A MX2021014093A MX 2021014093 A MX2021014093 A MX 2021014093A MX 2021014093 A MX2021014093 A MX 2021014093A MX 2021014093 A MX2021014093 A MX 2021014093A MX 2021014093 A MX2021014093 A MX 2021014093A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- parkinson
- methods
- compositions
- treating alzheimer
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- MTTHRRVVGMPYQG-ZDUSSCGKSA-N [(1r)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea Chemical compound C([C@H](C1=CC=2)CNC(=O)N)CCC1=CC=2S(=O)(=O)C1=CC=CC(F)=C1 MTTHRRVVGMPYQG-ZDUSSCGKSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a comprimidos para administración oral a un sujeto, que comprenden una cantidad terapéuticamente eficaz de SYN120, o una sal farmacéuticamente aceptable de este, en donde el comprimido está sustancialmente libre de lactosa. La presente invención también se refiere a métodos para tratar enfermedades o afecciones que incluyen el mal de Alzheimer y/o la enfermedad de Parkinson, que comprenden administrarle a un paciente que lo necesite comprimidos referentes a estas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402357P | 2016-09-30 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014093A true MX2021014093A (es) | 2021-12-10 |
Family
ID=61756894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003720A MX2019003720A (es) | 2016-09-30 | 2017-09-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
| MX2021014093A MX2021014093A (es) | 2016-09-30 | 2019-03-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003720A MX2019003720A (es) | 2016-09-30 | 2017-09-29 | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10314798B2 (es) |
| EP (1) | EP3518914A4 (es) |
| JP (1) | JP2019529502A (es) |
| AR (1) | AR109760A1 (es) |
| AU (2) | AU2017337053B2 (es) |
| CA (1) | CA3037059A1 (es) |
| IL (1) | IL265656A (es) |
| MX (2) | MX2019003720A (es) |
| TW (1) | TWI753952B (es) |
| WO (1) | WO2018064559A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI753952B (zh) | 2016-09-30 | 2022-02-01 | 美商拜歐蒂治療公司 | 治療阿茲海默氏病及帕金森氏病之組合物及方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039132D1 (de) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-Desmethylvenlafaxin-Succinat |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| AU2005318550B2 (en) * | 2004-12-21 | 2011-04-07 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
| WO2007147771A2 (en) * | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
| FR2974102B1 (fr) * | 2011-04-13 | 2014-08-22 | Rhodia Operations | Composition polyamide stabilisee |
| WO2015173133A1 (en) * | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| TWI753952B (zh) | 2016-09-30 | 2022-02-01 | 美商拜歐蒂治療公司 | 治療阿茲海默氏病及帕金森氏病之組合物及方法 |
-
2017
- 2017-09-29 TW TW106133810A patent/TWI753952B/zh not_active IP Right Cessation
- 2017-09-29 US US15/720,947 patent/US10314798B2/en not_active Expired - Fee Related
- 2017-09-29 JP JP2019517827A patent/JP2019529502A/ja active Pending
- 2017-09-29 MX MX2019003720A patent/MX2019003720A/es unknown
- 2017-09-29 WO PCT/US2017/054473 patent/WO2018064559A1/en unknown
- 2017-09-29 AU AU2017337053A patent/AU2017337053B2/en not_active Ceased
- 2017-09-29 CA CA3037059A patent/CA3037059A1/en not_active Abandoned
- 2017-09-29 EP EP17857545.2A patent/EP3518914A4/en not_active Withdrawn
- 2017-09-29 AR ARP170102714A patent/AR109760A1/es unknown
-
2019
- 2019-01-16 US US16/249,290 patent/US10973784B2/en active Active
- 2019-03-27 IL IL265656A patent/IL265656A/en unknown
- 2019-03-29 MX MX2021014093A patent/MX2021014093A/es unknown
-
2021
- 2021-03-01 US US17/188,413 patent/US20210177783A1/en not_active Abandoned
- 2021-12-01 AU AU2021277698A patent/AU2021277698A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10314798B2 (en) | 2019-06-11 |
| US20190142771A1 (en) | 2019-05-16 |
| EP3518914A1 (en) | 2019-08-07 |
| CA3037059A1 (en) | 2018-04-05 |
| US10973784B2 (en) | 2021-04-13 |
| AU2017337053A1 (en) | 2019-04-04 |
| WO2018064559A1 (en) | 2018-04-05 |
| IL265656A (en) | 2019-05-30 |
| EP3518914A4 (en) | 2020-06-10 |
| AU2017337053B2 (en) | 2021-09-02 |
| AU2021277698A1 (en) | 2021-12-23 |
| JP2019529502A (ja) | 2019-10-17 |
| MX2019003720A (es) | 2019-09-19 |
| TWI753952B (zh) | 2022-02-01 |
| AR109760A1 (es) | 2019-01-23 |
| US20210177783A1 (en) | 2021-06-17 |
| US20180092868A1 (en) | 2018-04-05 |
| TW201813638A (zh) | 2018-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| MY199968A (en) | Formulations of an lsd1 inhibitor | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
| MX2021002322A (es) | Nuevos metodos. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2018006247A (es) | Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| NZ778223A (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| ZA202200331B (en) | Naltrexone formulation | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага |